Actelion has presented detailed data on the drug it hopes will cement its position in the pulmonary arterial hypertension market, Uptravi. The shock-free data drove a small uptick in Actelion’s stock, but fell short of being the blockbuster-guaranteeing release some were hoping to see.

…read more

Source: Deep dive into Actelion’s Uptravi data calms investors as FDA decision date nears


0 No comments